An anti-CCN2 antibody (FG-3019) is in Phase III clinical trials for idiopathic pulmonary fibrosis and pancreatic cancer, and in Phase II for Duschenne's muscular dystrophy. Here, CCN2 is linked to pancreatic neoplasm.